Molecular Landscape of Non-Muscle Invasive Bladder Cancer

Joshua J. Meeks; Seth P. Lerner

doi:10.1016/j.ccell.2017.08.015

Molecular Landscape of Non-Muscle Invasive Bladder Cancer

Joshua J. Meeks, Seth P. Lerner^*

^*Corresponding author for this work

Urology

Research output: Contribution to journal › Short survey

5 Scopus citations

Abstract

In this issue of Cancer Cell, Hurst et al. report an integrated analysis of non-invasive (stage Ta) bladder cancer. Two genomic subtypes are distinguished by chromosome 9q loss, resulting in increased AKT/PI3K/mTOR signaling. Tumors from female patients have a higher frequency of KDM6A mutations. In this issue of Cancer Cell, Hurst et al. report an integrated analysis of non-invasive (stage Ta) bladder cancer. Two genomic subtypes are distinguished by chromosome 9q loss, resulting in increased AKT/PI3K/mTOR signaling and increased risk of recurrence. Tumors from female patients have a higher frequency of KDM6A mutations.

Original language	English (US)
Pages (from-to)	550-551
Number of pages	2
Journal	Cancer Cell
Volume	32
Issue number	5
DOIs	https://doi.org/10.1016/j.ccell.2017.08.015
State	Published - Nov 13 2017

Fingerprint

ASJC Scopus subject areas

Oncology
Cell Biology
Cancer Research

Cite this

Meeks, J. J., & Lerner, S. P. (2017). Molecular Landscape of Non-Muscle Invasive Bladder Cancer. Cancer Cell, 32(5), 550-551. https://doi.org/10.1016/j.ccell.2017.08.015

@article{8ddb607e70df4b69ae43f11d80ce03ae,

title = "Molecular Landscape of Non-Muscle Invasive Bladder Cancer",

abstract = "In this issue of Cancer Cell, Hurst et al. report an integrated analysis of non-invasive (stage Ta) bladder cancer. Two genomic subtypes are distinguished by chromosome 9q loss, resulting in increased AKT/PI3K/mTOR signaling. Tumors from female patients have a higher frequency of KDM6A mutations. In this issue of Cancer Cell, Hurst et al. report an integrated analysis of non-invasive (stage Ta) bladder cancer. Two genomic subtypes are distinguished by chromosome 9q loss, resulting in increased AKT/PI3K/mTOR signaling and increased risk of recurrence. Tumors from female patients have a higher frequency of KDM6A mutations.",

author = "Meeks, {Joshua J.} and Lerner, {Seth P.}",

year = "2017",

month = nov

day = "13",

doi = "10.1016/j.ccell.2017.08.015",

language = "English (US)",

volume = "32",

pages = "550--551",

journal = "Cancer Cell",

issn = "1535-6108",

publisher = "Cell Press",

number = "5",

}

TY - JOUR

T1 - Molecular Landscape of Non-Muscle Invasive Bladder Cancer

AU - Meeks, Joshua J.

AU - Lerner, Seth P.

PY - 2017/11/13

Y1 - 2017/11/13

N2 - In this issue of Cancer Cell, Hurst et al. report an integrated analysis of non-invasive (stage Ta) bladder cancer. Two genomic subtypes are distinguished by chromosome 9q loss, resulting in increased AKT/PI3K/mTOR signaling. Tumors from female patients have a higher frequency of KDM6A mutations. In this issue of Cancer Cell, Hurst et al. report an integrated analysis of non-invasive (stage Ta) bladder cancer. Two genomic subtypes are distinguished by chromosome 9q loss, resulting in increased AKT/PI3K/mTOR signaling and increased risk of recurrence. Tumors from female patients have a higher frequency of KDM6A mutations.

AB - In this issue of Cancer Cell, Hurst et al. report an integrated analysis of non-invasive (stage Ta) bladder cancer. Two genomic subtypes are distinguished by chromosome 9q loss, resulting in increased AKT/PI3K/mTOR signaling. Tumors from female patients have a higher frequency of KDM6A mutations. In this issue of Cancer Cell, Hurst et al. report an integrated analysis of non-invasive (stage Ta) bladder cancer. Two genomic subtypes are distinguished by chromosome 9q loss, resulting in increased AKT/PI3K/mTOR signaling and increased risk of recurrence. Tumors from female patients have a higher frequency of KDM6A mutations.

UR - http://www.scopus.com/inward/record.url?scp=85033667156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033667156&partnerID=8YFLogxK

U2 - 10.1016/j.ccell.2017.08.015

DO - 10.1016/j.ccell.2017.08.015

M3 - Short survey

C2 - 29136502

AN - SCOPUS:85033667156

VL - 32

SP - 550

EP - 551

JO - Cancer Cell

JF - Cancer Cell

SN - 1535-6108

IS - 5

ER -

Access to Document

10.1016/j.ccell.2017.08.015